Physician profile
Jun Sun
NPI 1306097209
$47,537.17
in general payments reported to CMS, 2019-2025
90 companies · $5,309 in 2025
The $5,309 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,356 · 2020: $2,030 · 2021: $7,115 · 2022: $13K · 2023: $5,459 · 2024: $7,415 · 2025: $5,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $7,406 · Travel and Lodging: $312 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,198.67 |
| Consulting Fee | $7,406.25 |
| Travel and Lodging | $311.91 |
| Education | $265.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $6,879.71 | 2022 | |
| Karyopharm Therapeutics INC. | $5,515.27 | 2020-2025 | Xpovio |
| Global Blood Therapeutics, INC. | $5,134.93 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $4,019.48 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Exelixis INC. | $3,898.27 | 2019-2025 | Cabometyx |
| Celgene Corporation | $2,805.32 | 2019-2025 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $2,206.11 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $1,247.39 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,041.61 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $979.96 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $964.37 | 2019-2025 | |
| Gilead Sciences, INC. | $882.77 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $712.75 | 2019-2025 | Opdivo, Eliquis, Augtyro |
| Daiichi Sankyo INC. | $691.77 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Abbvie INC. | $633.56 | 2020-2025 | Venclexta |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $621.70 | 2020-2025 | |
| Genentech USA, INC. | $603.84 | 2019-2025 | Venclexta, Tecentriq, Gazyva |
| Astellas Pharma US INC | $571.28 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Genzyme Corporation | $512.27 | 2019-2025 | |
| Seagen INC. | $436.02 | 2019-2023 | Padcev, Adcetris, Tivdak |
| Lilly USA, LLC | $396.42 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $373.11 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Eisai INC. | $350.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $349.90 | 2019-2025 | Iclusig, Advate, Alunbrig |
| Aveo Pharmaceuticals, INC. | $346.19 | 2022-2024 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $279.89 | 2019-2025 | |
| Beigene USA, INC. | $276.05 | 2022-2024 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $228.90 | 2022-2024 | Besremi |
| Glaxosmithkline, LLC. | $202.94 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Alexion Pharmaceuticals, INC. | $202.75 | 2020-2025 | Ultomiris |
| Stemline Therapeutics INC. | $189.53 | 2023-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $183.06 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Emd Serono, INC. | $177.79 | 2019-2024 | |
| Secura Bio, INC. | $173.23 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $169.53 | 2020-2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $167.78 | 2021-2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.73 | 2019-2025 | |
| Array Biopharma INC | $163.40 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $140.42 | 2021-2025 | Xermelo, Zoladex |
| Mirati Therapeutics, INC. | $133.25 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $129.01 | 2022-2024 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $124.24 | 2019-2024 | |
| Genmab U.S., INC. | $121.09 | 2023-2025 | Epkinly |
| Adc Therapeutics America, INC. | $104.43 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $100.50 | 2023-2025 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $94.20 | 2023-2025 | Rolvedon |
| Adaptive Biotechnologies Corporation | $85.49 | 2022-2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $84.84 | 2019-2023 | Xarelto |
| Kite Pharma, INC. | $82.96 | 2020-2024 | Yescarta |
| Blueprint Medicines Corporation | $81.40 | 2022-2023 | Ayvakit |
| Kyowa Kirin, INC. | $79.77 | 2022-2024 | Poteligeo |
| Coherus Oncology, INC. | $73.85 | 2022-2024 | |
| Myovant Sciences INC. | $67.27 | 2022 | |
| G1 Therapeutics, INC. | $66.33 | 2022-2023 | Cosela |
| Novocure INC. | $58.72 | 2025 | Optune Lua (Novottf-200t) |
| Covidien Lp | $56.93 | 2019 | |
| Sobi, INC | $56.11 | 2022-2025 | |
| Beone Medicines USA, INC. | $53.51 | 2025 | Tevimbra, Brukinsa |
| Servier Pharmaceuticals LLC | $51.00 | 2021-2025 | |
| Sirtex Medical INC | $49.33 | 2023-2024 | Sir-Spheres Microspheres |
| Morphosys, US INC. | $48.16 | 2023 | Monjuvi |
| Cti Biopharma Corp. | $47.44 | 2022-2023 | Vonjo |
| Alnylam Pharmaceuticals INC. | $47.28 | 2023-2025 | Givlaari |
| Foundation Medicine, INC. | $46.72 | 2019-2022 | |
| Springworks Therapeutics, INC. | $44.88 | 2024 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $44.26 | 2020-2023 | Monoferric |
| Deciphera Pharmaceuticals INC. | $41.87 | 2024-2025 | Qinlock, Tgct |
| Verastem, INC. | $38.82 | 2019 | |
| Blue Earth Diagnostics | $34.69 | 2023 | |
| Epizyme, INC. | $33.69 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $33.30 | 2019 | |
| Myriad Genetic Laboratories, INC. | $32.99 | 2022-2024 | Myrisk |
| Heron Therapeutics, INC. | $30.99 | 2019 | |
| Acrotech Biopharma INC. | $30.55 | 2024-2025 | Beleodaq |
| Tempus Ai, INC | $29.62 | 2024 | |
| Geron Corporation | $27.34 | 2025 | Rytelo |
| Immunogen, INC. | $24.36 | 2023 | Elahere |
| Biocon Biologics INC | $24.21 | 2024 | Ogivri |
| Mylan Institutional INC. | $22.57 | 2020 | |
| Fresenius Kabi USA, LLC | $22.54 | 2025 | |
| Caris Mpi, INC. | $22.35 | 2025 | Mi Cancer Seek |
| Accord Healthcare, INC. | $21.26 | 2025 | |
| Clovis Oncology, INC. | $21.18 | 2021 | |
| Dendreon Pharmaceuticals LLC | $20.88 | 2019 | |
| Dova Pharmaceuticals | $20.87 | 2021 | |
| Agios Pharmaceuticals, INC. | $20.67 | 2019 | |
| Eusa Pharma (US) LLC | $20.00 | 2021 | |
| Recordati_rare_diseases_inc. | $16.16 | 2024 | Sylvant |
| Acceleron Pharma, INC. | $15.43 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Xpovio $5,477Imfinzi $1,466Trodelvy $811Keytruda $762Enhertu $412Padcev $300Xtandi $267Cabometyx $257Elrexfio $250Adcetris $244Fotivda $208Lenvima $200Bosulif $199Lynparza $194Brukinsa $191Orserdu $190Opdivo $189Jaypirca $188Inlyta $186Orgovyx $181Iclusig $180Venclexta $179Kisqali $179Verzenio $177Ultomiris $176Erleada $173Jakafi $172Monjuvi $169Talzenna $153Epkinly $149Eliquis $139Krazati $133Onivyde $132Somatuline Depot $132Fabhalta $131Besremi $124Darzalex $120Welireg $119Tecvayli $119Braftovi $115Retevmo $112Stivarga $106Tecentriq $102Pemazyre $102Tukysa $102Pluvicto $97.47Scemblix $97.31Nubeqa $97.31Rolvedon $94.20Zejula $87.68Jemperli $87.68Imbruvica $87.52Reblozyl $86.06Vitrakvi $85.31Mektovi $81.90Lorbrena $80.16Oxbryta $78.67Gazyva $77.17Xofigo $76.31Ibrance $75.07Rezlidhia $75.00Tavalisse $75.00Itovebi $74.83Lumakras $73.23Keytruda Qlex $71.87Sarclisa $64.99Xermelo $64.20Bavencio $63.94Rybrevant $63.80Libtayo $62.83Tabrecta $61.24Mekinist $59.48Optune Lua (Novottf-200t) $58.72Poteligeo $58.50Udenyca $57.68Elahere $56.58Calquence $55.95Lunsumio $52.97Polivy $52.97Zoladex $52.62Tivdak $52.08Vonjo $51.64Clonoseq $50.69Sir-Spheres Microspheres $49.33Phesgo $48.46Perjeta $48.46Jevtana $48.27Tevimbra $47.86Givlaari $47.28Besponsa $46.78Nplate $45.60Xgeva $45.60Vectibix $45.60Lutathera $45.53Ogsiveo $44.88Blincyto $43.44Kyprolis $43.44Niktimvo $43.29Cosela $42.44Qinlock $41.87
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.